Juliane Mundorf

Juliane Mundorf

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2025 in Environmental Sciences Europe
Verified
Journal Article
Open access
PDF file
JMJuliane Mundorf
Juliane Mundorf
SSSamson Simon
Samson Simon
MEMargret Engelhard
Margret Engelhard
The European Commission has proposed to amend the EU GMO regulation, exempting certain genetically modified plants generated with new genomic techniques (NGTs) from risk assessment. In the suggested lex specialis so-called “category 1 NGT plants” would be treated as equivalent to conventionally bred plants, if they meet threshold-based criteria, which limit the number and size of induced genetic changes. Here, we critically analyze the scientific validity of these thresholds and show that the proposal oversimplifies genetic complexity—disregarding the biological context, mutational bias, and functional consequences. The proposal’s central claim of equivalence between NGT1 plants and conventionally bred plants is thus scientifically unfounded. Many conceivable genetic modifications produced with NGTs—including those created with CRISPR prime editing and AI-assisted design—could be highly complex and exceed the capabilities of conventional breeding. Nevertheless, the regulatory proposal treats all possible genetic changes as equally likely and overlooks the purpose and function of genetic edits. By eliminating case-by-case risk assessment, the proposal creates a regulatory gap that allows complex and novel traits to bypass scrutiny—undermining the EU’s legally binding precautionary principle. In contrast, a risk-based regulatory approach is needed to ensure safe and future-proof oversight of NGT plants.

30 November 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
FBFinja Bohle
Finja Bohle
RSRobin Schneider
Robin Schneider
JMJuliane Mundorf
Juliane Mundorf
LZLuise Zühl
Luise Zühl
SSSamson Simon
Samson Simon
MEMargret Engelhard
Margret Engelhard
The broad and rapid application of new genomic techniques (NGTs) such as CRISPR-Cas has led to a fast increase in the number of genetically modified crops. With the recently published EU Commission’s (EC) regulatory proposal on plants generated with NGTs (July 5, 2023) the process of admission of such genetically modified plants is aimed to get accelerated and simplified. NGT plant applications shall be categorized based on their molecular characteristics into category 1 NGT (NGT1) and category 2 NGT (NGT2), which is in divergence from the current legislation centered around Directive 2001/18/EC. In the regulatory proposal NGT2 plants are envisioned to undergo a reduced risk assessment while for NGT1 plants no risk assessment is foreseen at all. To demonstrate were the path of the proposal leads to in practice, we applied the proposed criteria for categorization to a list of NGT plant applications that are currently in the commercialization pipeline. A key finding is that out of those plant applications affected by the EC proposal, 94% would be classified as NGT1 and thus would receive a market approval without risk assessment, monitoring and sufficient labeling provisions. The remaining 6% of applications would be classified as NGT2 plants for which, in deviation from the current regulation, an adapted risk assessment is proposed. A screening of intended traits in the pipeline highlights that certain NGT1 plants can pose similar environmental risks (e.g. invasiveness) compared to other genetically modified organisms (GMOs), as defined in Directive 2001/18/EC. For example, NGT1 applications based on RNAi technology can exhibit insecticidal effects with potential side effects on non-target organisms (i.e. other insects). Our quantitative and case-specific elaboration on how the current EC regulatory proposal would affect the environment, health or consumer protection will be informative for decision makers and politicians.

3 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
JMJuliane Mundorf
Juliane Mundorf
SSSamson Simon
Samson Simon
MEMargret Engelhard
Margret Engelhard
The European Commission has proposed to amend the EU GMO regulation, exempting certain genetically modified plants generated with new genomic techniques (NGTs) from risk assessment. In the suggested lex specialis so-called “category 1 NGT plants” would be treated as equivalent to conventionally bred plants, if they meet threshold-based criteria, which limit the number and size of induced genetic changes. Here, we critically analyze the scientific validity of these thresholds and show that the proposal oversimplifies genetic complexity – disregarding the biological context, mutational bias, and functional consequences. The proposal’s central claim of equivalence between NGT1 plants and conventionally bred plants is thus scientifically unfounded. Many conceivable genetic modifications produced with NGTs – including those created with CRISPR prime editing and AI-assisted design – could be highly complex and exceed the capabilities of conventional breeding. Nevertheless, the regulatory proposal treats all possible genetic changes as equally likely and overlooks the purpose and function of genetic edits. By eliminating case-by-case risk assessment, the proposal creates a regulatory gap that allows complex and novel traits to bypass scrutiny – undermining the EU’s legally binding precautionary principle. In contrast, a risk-based regulatory approach is needed to ensure safe and future-proof oversight of NGT plants.

8 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JMJuliane Mundorf
Juliane Mundorf
SSSamson Simon
Samson Simon
The European Union (EU) recently adopted Regulation (EU) 2026/1388 for plants developed with new genomic techniques (NGTs). Under this Regulation, Category 1 NGT plants are exempt from most EU requirements applicable to genetically modified organisms, provided that they meet, among other things, the criteria of equivalence defined in Annex I. Although these criteria consist of simplified molecular characteristics and numerical thresholds, their molecular, analytical, and regulatory verification is more demanding than the legislative wording may suggest at a first glance. Demonstrating compliance requires comprehensive identification of relevant genetic modifications, alignment with genome annotations, evaluation of the gene pool for conventional breeding purposes, assessment of polyploid genomes, and attribution of genetic changes to the use of NGTs. Accordingly, enforcement of Annex I will require robust technical guidance defining sequencing standards, bioinformatic tasks, annotation requirements, attribution specifications, and harmonized counting methodologies. To this end, we propose a seven-step workflow from data-generation to regulatory evaluation in order to ensure a reliable and standardized verification process for Category 1 NGT categorization.